Clinical Trials Logo

Barrett Esophagus clinical trials

View clinical trials related to Barrett Esophagus.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06381583 Completed - Esophageal Cancer Clinical Trials

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

EMERALD
Start date: April 15, 2023
Phase:
Study type: Observational

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for the early detection of esophageal adenocarcinoma and its precursor lesions, using advanced machine learning and state-of-the-art biological analyses.

NCT ID: NCT05628441 Completed - Barrett Esophagus Clinical Trials

Real-time Computer Aided Detection of Barrett's Neoplasia

Start date: May 16, 2022
Phase:
Study type: Observational [Patient Registry]

In the real-time pilot study, the performance of a recently developed Computer Aided Detection (CADe) system will be investigated in 30 patients during real-time live endoscopic examination. Three expert endoscopists in the field of Barrett's esophagus and endoscopic resection techniques will perform the inclusions following a standardized data acquisition protocol. In total, 15 patients with a visible neoplastic lesion in their Barrett's esophagus and 15 patients without any visible abnormalities in their Barrett's esophagus will be included in this study. Outcomes: to investigate feasibility of the use of the CADe system in the endoscopy suite, to investigate the performance of the CADe system when used by endoscopists.

NCT ID: NCT05200325 Completed - Barrett Esophagus Clinical Trials

Clinical Utility Evidence for TissueCypher®

Start date: June 6, 2021
Phase: N/A
Study type: Interventional

Cernostics has developed a new diagnostic test, and this study will measure how gastroenterologists and foregut surgeons make diagnostic and treatment decisions when presented with different information in the context of simulated clinical cases. The results of this study could contribute to improved quality of care for patients by encouraging better care practices and adherence to evidence-based guidance. The data from this study will be provided to all participating physicians and submitted to a national journal for publication. The study plans to enroll up to 249 physicians.

NCT ID: NCT04656392 Completed - Esophageal Cancer Clinical Trials

Early Detection of Barrett's Esophagus in Participants With Reflux Symptoms in Primary Care

ELECTRONIC
Start date: April 20, 2021
Phase: N/A
Study type: Interventional

In the Netherlands, the incidence of esophageal adenocarcinoma (EAC) is increasing. In addition, EAC has a dismal prognosis. Therefore, screening for Barrett's Esophagus (BE) has stimulated interest. Although BE is a known precursor of EAC, a minority of patients with EAC are known with a previous diagnosis of BE. A non-invasive screening tool, such as breath testing, could select patients at risk for BE, after which unsedated transnasal endoscopy (uTNE) can confirm or exclude the diagnosis. The objective is to determine the accuracy and acceptability of a non-invasive screening strategy i.e. breath testing followed by uTNE for BE and EAC.

NCT ID: NCT04587310 Completed - Barrett Esophagus Clinical Trials

Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study

Start date: October 1, 2008
Phase:
Study type: Observational

Introduction Laparoscopic Sleeve Gastrectomy (LSG) is one of the most prevalent approaches to tackle obesity and its co-morbidities. The main complication following the LSG is Gastro-esophageal reflux disease (GERD), with most patients developing worsening symptoms of GERD, and a small number progressing to Barrett's esophagus. This retrospective analysis aims to assess the rate of GERD pre- and post- LSG as well as the rate of progression to Barrett's. Methods Data was collected from 1639 patients. 92 patients fit our inclusion criteria. Data was then analyzed and summarized against similar literature

NCT ID: NCT04392167 Completed - Barrett Esophagus Clinical Trials

a/LCI-OCT Pilot in Esophagus

Start date: November 24, 2020
Phase: N/A
Study type: Interventional

This study will test a newly developed dual modality probe, including optical coherence tomography (OCT) and angle-resolved low-coherence interferometry (a/LCI), in the human esophagus to determine 1) whether adequate tissue contact can be attained by the probe to acquire high quality images, and 2) to identify if these images can discern whether the imaged tissue is squamous or Barrett's Esophagus (BE) epithelium. This pilot study will test the operating characteristics of the probe and collect data for further optimization of the a/LCI-OCT device.

NCT ID: NCT04329000 Completed - Barrett Esophagus Clinical Trials

On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

Start date: February 2, 2010
Phase: N/A
Study type: Interventional

On-demand PPI therapy is feasible for the long-term treatment of patients with Barrett's esophagus.

NCT ID: NCT04316975 Completed - Clinical trials for Barretts Esophagus With Dysplasia

Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Start date: April 10, 2020
Phase: N/A
Study type: Interventional

To evaluate association between mutational load (ML) from esophageal biopsy specimens in pre-endoscopic eradication therapy (EET) in Barrett's Esophagus (BE) or Intramucosal adenocarcinoma (IMC) patients and treatment resistance (treatment resistance will be defined as disease recurrence and/or need for additional intervention such as increased acid suppression, need for anti-reflux surgery, or use of alternate ablative modality).

NCT ID: NCT04301986 Completed - GERD Clinical Trials

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

Start date: August 11, 2020
Phase: N/A
Study type: Interventional

To assess patient acceptance and preference among screening modalities, Esophagogastroduodenoscopy (EGD), Transnasal Esophagoscopy (TNE), and Cytosponge for Barrett's esophagus (BE). Subjects will undergo administration of Cytosponge and transnasal endoscopy (TNE) prior to their scheduled clinically indicated upper endoscopy performed per routine standard of care. Following the procedure, a follow-up phone call will be made during which an impact of events scale related to the subjective distress of each procedure, a preference and acceptance questionnaire, and adverse events related to study participation will be collected.

NCT ID: NCT04293458 Completed - Barrett Esophagus Clinical Trials

Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE

ESOGUARDBE1
Start date: February 28, 2020
Phase: N/A
Study type: Interventional

The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines.